Cargando…
Chimeric Antigen Receptor T Cells in Glioblastoma—Current Concepts and Promising Future
Glioblastoma (GBM) is a highly aggressive primary brain tumor that is largely refractory to treatment and, therefore, invariably relapses. GBM patients have a median overall survival of 15 months and, given this devastating prognosis, there is a high need for therapy improvement. One of the therapeu...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340625/ https://www.ncbi.nlm.nih.gov/pubmed/37443804 http://dx.doi.org/10.3390/cells12131770 |